1-115664171-G-A
Position:
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_138959.3(VANGL1):c.715G>A(p.Val239Ile) variant causes a missense change. The variant allele was found at a frequency of 0.0000434 in 1,613,950 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.000059 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000042 ( 0 hom. )
Consequence
VANGL1
NM_138959.3 missense
NM_138959.3 missense
Scores
1
5
13
Clinical Significance
Conservation
PhyloP100: 5.59
Genes affected
VANGL1 (HGNC:15512): (VANGL planar cell polarity protein 1) This gene encodes a member of the tretraspanin family. The encoded protein may be involved in mediating intestinal trefoil factor induced wound healing in the intestinal mucosa. Mutations in this gene are associated with neural tube defects. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Feb 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -6 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.23214778).
BS2
High AC in GnomAd4 at 9 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
VANGL1 | NM_138959.3 | c.715G>A | p.Val239Ile | missense_variant | 4/8 | ENST00000355485.7 | |
VANGL1 | NM_001172412.2 | c.715G>A | p.Val239Ile | missense_variant | 4/8 | ||
VANGL1 | NM_001172411.2 | c.709G>A | p.Val237Ile | missense_variant | 4/8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
VANGL1 | ENST00000355485.7 | c.715G>A | p.Val239Ile | missense_variant | 4/8 | 1 | NM_138959.3 | P3 | |
VANGL1 | ENST00000310260.7 | c.715G>A | p.Val239Ile | missense_variant | 4/8 | 1 | P3 | ||
VANGL1 | ENST00000369509.1 | c.715G>A | p.Val239Ile | missense_variant | 3/7 | 1 | P3 | ||
VANGL1 | ENST00000369510.8 | c.709G>A | p.Val237Ile | missense_variant | 4/8 | 1 | A1 |
Frequencies
GnomAD3 genomes AF: 0.0000591 AC: 9AN: 152172Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
9
AN:
152172
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000518 AC: 13AN: 250772Hom.: 0 AF XY: 0.0000738 AC XY: 10AN XY: 135554
GnomAD3 exomes
AF:
AC:
13
AN:
250772
Hom.:
AF XY:
AC XY:
10
AN XY:
135554
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000417 AC: 61AN: 1461778Hom.: 0 Cov.: 32 AF XY: 0.0000481 AC XY: 35AN XY: 727166
GnomAD4 exome
AF:
AC:
61
AN:
1461778
Hom.:
Cov.:
32
AF XY:
AC XY:
35
AN XY:
727166
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000591 AC: 9AN: 152172Hom.: 0 Cov.: 32 AF XY: 0.0000404 AC XY: 3AN XY: 74330
GnomAD4 genome
AF:
AC:
9
AN:
152172
Hom.:
Cov.:
32
AF XY:
AC XY:
3
AN XY:
74330
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
5
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Pathogenic:1Uncertain:2
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not provided Uncertain:2
Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The VANGL1 p.V239I variant was identified in 1 of 288 proband chromosomes (frequency: 0.0034) from individuals or families with caudal regression and was not identified in 212 control chromosomes from healthy individuals (Kibar_2007_PMID:17409324). The variant was identified in dbSNP (ID: rs121918218) and ClinVar (classified as likely pathogenic in 2016 by GeneDx). The variant was not identified in Cosmic or LOVD 3.0. The variant was identified in control databases in 17 of 282170 chromosomes (0 homozygous) at a frequency of 0.00006025 (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: European (non-Finnish) in 15 of 128536 chromosomes (freq: 0.000117), East Asian in 1 of 19952 chromosomes (freq: 0.00005) and African in 1 of 24968 chromosomes (freq: 0.00004), but was not observed in the Latino, Ashkenazi Jewish, European (Finnish), Other or South Asian populations. The p.Val239Ile variant was identified in a 10-year-old Italian girl who had a severe form of caudal regression and was also found in her brother who had a milder form of the disease, dermal sinus (Kibar_2007_PMID:17409324). However, the variant was also found in their unaffected mother, suggesting incomplete penetrance or variable expressivity (Kibar_2007_PMID:17409324). The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. The p.Val239 residue is conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. However, in a protein-protein interaction assay the p.V239I variant was found to have a deleterious affect on the protein, abolishing interaction of the VANGL1 protein with its binding partners (Kibar_2007_PMID:17409324). In a zebrafish model, knockdown/rescue experiments and overexpression assays suggested that the p.V239I variant results in a loss of function allele that affects protein function during embryonic development (Reynolds_2010_PMID: 20043994). In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jun 01, 2023 | Published functional studies of V239I indicate that it inhibits the interaction of VANGL1 with Dvl proteins, potentially inhibiting molecular signaling during gastrulation and neural-tube closure (Kibar et al., 2007; Renolds et al., 2010); Identified in an individual with caudal regression with lipomyeloschisis, anorectal malformation, hydromyelia, and a tethered spinal cord. The V239I variant was also present in her unaffected mother and mildly affected brother who had dermal sinus (Kibar et al., 2007); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 25208524, 17409324, 31589614, 20043994) - |
Caudal regression sequence Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 05, 2007 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Uncertain
T
BayesDel_noAF
Uncertain
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
T;.;T;T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Pathogenic
D
LIST_S2
Benign
T;T;.;.
M_CAP
Benign
D
MetaRNN
Benign
T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Benign
L;.;L;L
MutationTaster
Benign
A;A;A;A
PrimateAI
Uncertain
T
PROVEAN
Benign
N;N;N;N
REVEL
Uncertain
Sift
Benign
T;T;T;T
Sift4G
Benign
T;T;T;T
Polyphen
B;B;B;B
Vest4
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at